Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)

Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks

NCT Number	NCT07706530
Lead Sponsor	Clarent Biopharma, Inc.
Conditions	Arthritic Psoriasis
Enrollment	240 participants
Start Date	2026-07
Primary Completion	2027-02 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-16